Vertex announces positive results from ongoing phase 1/2 study of vx-880 for the treatment of type 1 diabetes presented at the american diabetes association 84th scientific sessions

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today presented new data from its phase 1/2 clinical trial of vx-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (t1d) with impaired hypoglycemic awareness and severe hypoglycemic events (shes). these updated data on 12 patients who received the full dose as a single infusion in parts b and c of the trial are consistent with previously reported positive.
VRTX Ratings Summary
VRTX Quant Ranking